PROGRAM (FEBRUARY 17 – 20)

• Academic Opportunities - Suresh Ramalingam, USA
• Options in Industry - Leora Horn, USA
• FDA and Regulatory Opportunities - Harpreet Singh, USA
• Private Practice Opportunities - Edward Kim, USA
• Basic Science Opportunities - John Minna, USA
• Cancer Therapy Evaluation Program Externship Fellow Program, NCI - Shakun Malik, USA
• Live Panel Discussion - Lecia Sequist, USA, Peter Ujhazy, USA, Luis Raez, USA, Paul Bunn, USA, Neal Ready, USA, Frances Shepherd, Canada

*Sign-up is required for this session by Monday, February 15 (19:00 EST) via re-accessing your registration. Instructions to sign up for the session will be emailed to you by Wednesday, February 10. Please contact [email protected] with the registration invoice attached if you did not receive the instructions. 

• Opening Remarks
• Cell Free DNA - Max Diehn, USA
• Live Panel Discussion, Paul Bunn, USA

• EGFR Combinations (MET, Chemo, VEGF, Small Cell) - Helena Yu, USA
• EGFR TKI Combination Therapies: C797S, MEK, AURORA Kinase - Collin Blakely, USA
• EGFR Exon 20 Insetions: Novel TKIs, Amivantamab and Other Treatment Options - Zofia Piotrowska, USA
• Persister Biology - Christine Lovly, USA
• Live Panel Discussion - Natasha Leighl, Canada, Brian Henick, USA, Dara Aisner, USA, Jacqulyne Robichaux, USA, Hatim Husain, USA, Trever Bivona, USA, Balazs Halmos, USA, Heather Wakelee, USA

• New Studies of Approved Agents: Crizotinib, Ceritinib, Alectinib, Lorlatinib, Ensartinib - New Data and Resistance Mechanisms - Ignatius (Sai-Hong) Ou, USA
• New Agents Not Yet Approved: Repotectinib, DS6051b - Jessica Lin, USA
• Combinations: VEGF, Trametinib, CDK4/6, mTOR - Shirish Gadgeel, USA
• Continuing TKI Beyond Progression (All Drivers) - Ross Camidge, USA
• Live Panel Discussion - Thomas Stinchcombe, USA, Elaine Shum, USA, Mark Awad, USA, Tejas Patil, USA, Greg Otterson, USA, Sandip Patel, USA, Vincent Lam, USA, Deborah Doroshow, USA

• Sotorasib for KRAS G12C - Bob Li, USA
• Adagrasib (MRTX849) - Lyudmila Bazhenova, USA
• Effect of Co-Mutations - John Heymach, USA
• KRAS G12C Inhibitor Combinations - Gregory Riely, USA
• Live Panel Discussion - David Spigel, USA, Wade Iams, USA, Michael Cheng, USA, Sarah Goldberg, USA, Vamsidhar Velcheti, USA, Adrian Sacher, Canada, Ferdinandos Skoulidis, USA, Rajwanth Veluswamy, USA

• MET - Rebecca Heist, USA
• RET Fusion-Positive Lung Cancers - Alex Drilon, USA
• BRAF - Ibiayi Dagogo-Jack, USA
• HER2, NTRK, NRG1 "Too Many Topics for a Pun" - Stephen Liu, USA
• Live Panel Discussion, Karen Kelly, USA, Xiuning Le, USA, Matthew Gubens, USA, Fadlo Khuri, Lebanon, Jonathan Riess, USA, Hirva Mamdani, USA, Erin Larkins, USA, Paul Paik, USA

• Immunotherapy + Multi-kinase Inhibitors - Joel Neal, USA
• Immunotherapy Combos: LAG-3, TIM-3, TIGIT, OX-40 - Rachel Sanborn, USA
• IO + PARPi, VEGFi - Melissa Johnson, USA
• Immunotherapy Combinations CTLA-4, 41BB, ICOS - Jarushka Naidoo, Ireland
• Live Panel Discussion - Julie Brahmer, USA, Karen Reckamp, USA, Joshua Bauml, USA, John Wrangle, USA, Rosalyn Juergens, Canada, James Welsh, USA, Shadia Jalal, USA Parneet Cheema, Canada

• TMB and Neoantigens - Matthew Hellmann, USA
• Statistical Models - Yu Shyr, USA
• Multiplexed Tissue Analysis and Tumor Immune Microenvironment - Kurt Schalper, USA
• Liquid Biopsy Approaches for Precision Immuno-Oncology - Valsamo Anagnastou, USA
• Live Panel Discussion - Edward Garon, USA, Christian Rolfo, USA, Diane Tseng, USA, Dwight Owen, USA, Estelamari Rodriguez, USA, Katerina Politi, USA, David Kozono, USA, Aaron Mansfield, USA

• Personalized Cancer Vaccines - Justin Gainor, USA
• Cellular Therapies, Adoptive T-cells - Benjamin Creelan, USA
• Intratumoral Injections/TILs - Scott Gettinger, USA
• Aiming the Immune System at Mutation-driven Tumors - Charu Aggarwal, USA
• Live Panel Discussion - Naiyer Rizvi, USA, Kristen Marrone, USA, Kathryn Arbour, USA, Nasser Hanna, USA, Aparna Hegde, USA, Erin Schenk, USA, Kai He, USA, Joshua Reuss, USA

• Pharmacology and Toxicity of Antibody Drug Conjugates - Alex Adjei, USA
• Antibody Drug Conjugates for HER2 and HER3 - Pasi Janne, USA
• Trop2 ADCs: IMMU132 & DS-1062 - Ben Levy, USA
• Other ADCs - Martin Edelman, USA
• Live Panel Discussion - Hossein Borghaei, USA, Jacob Sands, USA, David Gerber, USA, Conor Steuer, USA, Jennifer Carlisle, USA, Jared Weiss, USA, Liza Villaruz, USA, Ryan Gentzler, USA

• Chemo-IO in ES-SCLC - Ticiana Leal, USA
• SCLC: Emerging Agents (Lurbinectedin, Lipo Irinotecan, APG-1252 [Pelcitoclax]) - Gregory Kalemkerian, USA
• Emerging Immunotherapy Approaches (AMG 757, GD-2 CAR & others) - Taofeek Owonikoko, USA
• New Therapeutic Targets for SCLC - Charles Rudin, USA
• Radiotherapy Issues in SCLC - Kristin Higgins, USA
• Live Panel Discussion - Anne Chiang, USA, Victoria Lai, USA, Lauren Byers, USA, Puneeth Iyengar, USA, Benjamin Drapkin, USA, Anne Tsao, USA, Afshin Dowlati, USA, Jonathan Lehman, USA

• Neratinib Efficacy in Patients with EGFR Exon 18-Mutant Non-Small Cell Lung Cancer (NSCLC): Findings from the SUMMIT Basket Trial - Amy Cummings, USA
• Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer - Triparna Sen, USA
• Beyond Steroids Immunosuppressants in Steroid-refractory Immune Related Adverse Events - Jia Luo, USA
• Identifying B7-H6 as a Prospective Immunotherapy Target in Small Cell Lung Cancer - Portia Thomas, USA
• Discussant - Ravi Salgia, USA
• Live Panel Discussion - All Speakers

• PACIFIC Trials - Jhanelle Gray, USA
• Stage III Inoperable NSCLC: Other IO Agents - Christine Bestvina, USA
• Ongoing Key Stage III Lung Cancer Trials in the NCTN and Beyond - Nathan Pennell, USA
• New Innovations in Radiation Therapy for Lung Cancer - Jeffrey Bradley, USA
• Live Panel Discussion - Andrea Bezjak, Canada, Henry Park, USA, Jonathan Spicer, Canada, Antoinette Wozniak, USA, Jyoti Patel, USA, Penelope Bradbury, Canada, Angel Qin, USA, Max Diehn, USA

• Neoadjuvant Immunotherapy and Chemotherapy Plus Immunotherapy with Adjuvant Immunotherapy: Phase 2 Results and Ongoing Trials - Patrick Forde, USA
• Adjuvant Immunotherapy and Chemo-Immunotherapy: Phase 2 Results and Ongoing Trials - Greg Durm, USA
• Neoadjuvant and Adjuvant TKI Trials - Jamie Chaft, USA
• Pathologic Response Evaluation - Sanja Dacic, USA
• Live Panel Discussion - Neal Ready, USA, Jay Lee, USA, Hina Saeed, USA, Jessica Donington, USA, Brendon Stiles, USA, Catherine Shu, USA, Ray Osarogiagbon, USA, Thomas Marron, USA

• Academic Publishing: Now and into the Future - Alex Adjei, USA
• Live Panel Discussion - Lecia Sequist, USA